Dr. Philip Trackman is a Professor and the Director of Graduate Programs in the Department of Molecular and Cell Biology at the Boston University Henry M. Goldman School of Dental Medicine. Dr. Trackman is also an important member of the Oral Cancer Research Initiative (OCRI) and is currently investigating the molecular mechanisms of the connective tissue enzyme, lysyl oxidase, and its potential therapeutic effects in oral cancer.
Dr. Trackman became interested in cancer research in 1990, after cloning lysyl oxidase for the very first time. This enzyme family has tumor inhibitory properties and also enhances tissue fibrosis and metastasis. In the context of the OCRI, Dr. Trackman is working to investigate the two therapeutic opportunities which these findings suggest. His first aim is to explore how to inhibit the harmful activity of the active enzymes, while taking advantage of the tumor growth inhibitory activity of the lysyl oxidase propeptide. The lysyl oxidase propeptide was shown by Dr. Trackman’s lab in 2004 to be responsible for the tumor growth inhibitory properties of lysyl oxidase. His lab has confirmed this in animal models of both breast and prostate cancer, and recently also in oral cancer. Dr. Trackman collaborated on this project with Research Assistant Professor Dr. Manish Bais, who is also an OCRI investigator.
Dr. Trackman’s ongoing research will establish the extent to which new and powerful lysyl oxidase family enzyme activity inhibitors can block human oral cancer tumor growth and/or metastasis in mice. This work is funded by the OCRI’s Etiology and Pathogenesis of Oral Cancer Affinity Research Collaborative (ARC) as a part of Boston University’s Evans Center for Interdisciplinary Biomedical Research. In addition, modifications to the structure of the lysyl oxidase propeptide are underway with the goal of enhancing its tumor growth inhibitory properties, and also to identify its most important binding partners in its ability to inhibit tumor growth. This research is supported by funding from the NIH.
- Director of Graduate Programs, Molecular & Cell Biology, Molecular & Cell Biology, Boston University Henry M. Goldman School of Dental Medicine
- Research Assistant Professor, Biochemistry, Boston University School of Medicine
- Mentor for Graduate Medical Students, Boston University School of Medicine, Graduate Medical Sciences
- Boston University, PhD
- College of Wooster, BA
- Published on 5/13/2019
Mahjour F, Dambal V, Shrestha N, Singh V, Noonan V, Kantarci A, Trackman PC. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB. Oncogenesis. 2019 May 13; 8(5):34. PMID: 31086173.
- Published on 7/3/2018
de la Cueva A, Emmerling M, Lim SL, Yang S, Trackman PC, Sonenshein GE, Kirsch KH. A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer. Carcinogenesis. 2018 07 03; 39(7):921-930. PMID: 29579155.
- Published on 5/22/2018
Saxena D, Mahjour F, Findlay AD, Mously EA, Kantarci A, Trackman PC. Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative Processes. J Dent Res. 2018 Oct; 97(11):1277-1284. PMID: 29787337.
- Published on 1/12/2018
Herzog CR, Berzins DW, DenBesten P, Gregory RL, Hargreaves KM, Messer RLW, Mina M, Mooney MP, Paine ML, Phillips C, Presland RB, Quivey RG, Scannapieco FA, Sheridan JF, Svoboda KKH, Trackman PC, Walker MP, Walker SG, Wang CY, Hu JCC. Oral Sciences PhD Program Enrollment, Graduates, and Placement: 1994 to 2016. J Dent Res. 2018 05; 97(5):483-491. PMID: 29328868.
- Published on 10/30/2017
Trackman PC. Functional importance of lysyl oxidase family propeptide regions. J Cell Commun Signal. 2018 Mar; 12(1):45-53. PMID: 29086201.
- Published on 10/28/2017
Trackman PC, Bais MV. Measurement of lysyl oxidase activity from small tissue samples and cell cultures. Methods Cell Biol. 2018; 143:147-156. PMID: 29310775.
- Published on 7/22/2017
Bais MV, Kukuruzinska M, Trackman PC. Corrigendum to "Orthotopic non-metastatic and metastatic oral cancer mouse models" [Oral Oncol. 51(5) (2015) 476-482]. Oral Oncol. 2017 09; 72:201. PMID: 28743466.
- Published on 5/1/2017
Kim D, Mecham RP, Trackman PC, Roy S. Downregulation of Lysyl Oxidase Protects Retinal Endothelial Cells From High Glucose-Induced Apoptosis. Invest Ophthalmol Vis Sci. 2017 May 01; 58(5):2725-2731. PMID: 28538980.
- Published on 4/25/2017
Sánchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE. UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells. J Cell Biochem. 2017 Aug; 118(8):2347-2356. PMID: 28106301.
- Published on 1/1/2017
Trackman PC, Saxena D, Bais MV. TGF-ß1- and CCN2-Stimulated Sirius Red Assay for Collagen Accumulation in Cultured Cells. Methods Mol Biol. 2017; 1489:481-485. PMID: 27734398.
View 100 more publications: View full profile at BUMC